List view / Grid view
The FDA has approved Lutathera for the treatment of a…
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
The FDA has expanded the approved use of Lynparza to…
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
Hemlibra has been approved to prevent the frequency of bleeding…
Hemlibra has been approved to prevent the frequency of bleeding episodes in patients who have developed FVIII inhibitors...
The FDA has expanded the approval of Zelboraf to include…
The FDA has expanded the approval of Zelboraf to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare cancer of the blood...
The FDA has granted accelerated approval to Calquence for the…
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...
The FDA has approved Verzenio to treat advanced or metastatic…
The FDA has approved Verzenio to treat advanced or metastatic breast cancer that has progressed after taking therapy...
The FDA has approved Mylotarg for the treatment of adults…
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
The FDA has approved Besponsa for the treatment of adults…
The FDA has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia...
The U.S. Food and Drug Administration has granted the approval…
The U.S. Food and Drug Administration has granted the approval of Idhifa to Celgene Corporation and RealTime IDH2 Assay to Abbott Laboratories...
